What companies does Bristol Myers Squibb own?
Our medicines
- ABECMA® (idecabtagene vicleucel)
- ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)
- AZACTAM® (aztreonam for injection, USP)
- BREYANZI® (lisocabtagene maraleucel)
- BARACLUDE® (entecavir)
- DROXIA® (hydroxyurea)
- ELIQUIS® (apixaban)
- EMPLICITI® (elotuzumab)
What does Bristol Myers company do?
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
How many drugs does Bristol Myers have?
Bristol-Myers Squibb Company manufactures, markets and/or distributes more than 34 drugs in the United States. Medications listed here may also be marketed under different names in different countries.
Who manufactures hydrea?
Bristol-Myers Squibb, Euticals, and Tecoland are among the top manufacturers and providers in the hydroxyurea market. Suppliers sell both generic and brand-name hydroxyurea preparations. The retail price of hydroxyurea tablets ranges from 17.55 USD to 29.24 USD per 100 (500mg) pills.
When did Bristol-Myers Squibb go public?
1933
In 1929 Bristol-Myers was absorbed by a giant holding company, Drug Inc., which, however, dissolved during the Great Depression. Bristol-Myers became a publicly traded company in 1933.
Who is the maker of Plavix?
Bristol-Myers Squibb – Sanofi Pharmaceuticals
Plavix is made under a Bristol-Myers Squibb – Sanofi Pharmaceuticals partnership.
What drugs does Celgene make?
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias.
What is Abatacept used for?
“Abatacept (Orencia) was developed by Bristol-Myers-Squibb for the treatment of rheumatoid arthritis (RA).” Twenty-five RA patients were enrolled for treatment with single and multiple doses of abatacept.
What are the clinical trials of Abatacept?
Phase III clinical trials started in April 2007 and concluded in July 2008. The trial included three major studies on AIM (abatacept in inadequate responders to methotrexate), ATTAIN (abatacept trial in treatment of anti-TNF inadequate responders) and ASSURE (abatacept study of safety in use with other RA therapies).
What is AB Abatacept (Orencia)?
Abatacept (Orencia) was developed by Bristol-Myers-Squibb for the treatment of rheumatoid arthritis (RA). It is a biologic drug which contains a selective co-stimulation modulator. RA affects about one percent of the world’s population.
When was Abatacept approved in the US?
The US Food and Drug Administration approved the drug in December 2005, followed by the European Commission in July 2010. In August 2011, the FDA approved a subcutaneous (SC) formulation of abatacept for treating adults with moderate to severe RA.